News & Updates

Vonoprazan bests PPIs in relieving GERD symptoms in latest meta-analysis

14 Sep 2021 by

The potassium-competitive acid blocker vonoprazan appears to be more effective than proton pump inhibitors (PPIs) in healing severe erosive esophagitis and relieving the symptoms of gastroesophageal reflux disease (GERD), according to a meta-analysis presented at APDW 2021.

Vonoprazan bests PPIs in relieving GERD symptoms in latest meta-analysis

14 Sep 2021

Cannabis, cannabinoids do not induce clinical remission but improve symptoms, QOL in IBD

14 Sep 2021

Cannabis and cannabinoids are not effective in inducing clinical remission or reducing inflammation in patients with inflammatory bowel disease (IBD), but they appear to significantly improve patient-reported symptoms and quality of life (QOL), suggest the results of a systematic review and meta-analysis.

Cannabis, cannabinoids do not induce clinical remission but improve symptoms, QOL in IBD

14 Sep 2021

Vonoprazan-based regimen shows treatment potential against H. pylori

14 Sep 2021 by

A 14-day quadruple therapeutic regimen containing vonoprazan – a first-in-class potassium-competitive acid blocker (P-CAB) with reportedly stronger acid inhibition than proton pump inhibitors – provided an excellent cure rate for Helicobacter pylori (H. pylori) infection in patients with high clarithromycin and quinolone resistance regardless of CYP3A4/5 genotypic polymorphism, according to the prospective VQ-HP trial presented at APDW 2021.

Vonoprazan-based regimen shows treatment potential against H. pylori

14 Sep 2021

TDF better than entecavir at reducing HCC risk, improving survival in CHB patients

13 Sep 2021

Tenofovir disoproxil fumarate (TDF) appears to provide a lower risk of hepatocellular carcinoma (HCC) development and longer survival in patients with chronic hepatitis B (CHB) than entecavir, particularly among treatment-naïve patients and those with underlying cirrhosis, reveals a study.

TDF better than entecavir at reducing HCC risk, improving survival in CHB patients

13 Sep 2021

Does PPI use affect clinical outcomes in COVID-19 patients?

13 Sep 2021 by

According to a Hong Kong study presented at APDW 2021, the use of proton pump inhibitors (PPIs) is not associated with adverse clinical outcomes in individuals with COVID-19.

Does PPI use affect clinical outcomes in COVID-19 patients?

13 Sep 2021

Vitamin D supplementation beneficial in children with IBD

12 Sep 2021

Supplementation with vitamin D appears to confer benefits on children with inflammatory bowel disease (IBD), suggests a recent study.

Vitamin D supplementation beneficial in children with IBD

12 Sep 2021

Double immunochemical faecal occult blood test most cost-effective CRC screening strategy

10 Sep 2021

While any colorectal cancer (CRC) screening strategy proves more cost-effective compared with no screening, double immunochemical faecal occult blood test appears to be the most economical, according to a study from China.

Double immunochemical faecal occult blood test most cost-effective CRC screening strategy

10 Sep 2021

Reduced-dose S1 + oxaliplatin combo therapy preserves QoL in older patients with mCRC

10 Sep 2021 by

The combination of reduced-dose S1 and oxaliplatin (SOx) chemotherapy preserves quality of life (QoL) and physical function in vulnerable older patients with metastatic colorectal cancer (mCRC), according to a subgroup analysis of the NORDIC9* study presented at ESMO GI 2021.

Reduced-dose S1 + oxaliplatin combo therapy preserves QoL in older patients with mCRC

10 Sep 2021

Antibiotic exposure tied to increased early-onset CRC risk

09 Sep 2021 by

Antibiotic exposure may be associated with an increased risk of early-onset colorectal cancer (CRC), according to a study from Scotland presented at ESMO GI 2021.

Antibiotic exposure tied to increased early-onset CRC risk

09 Sep 2021

Best practices for gastroesophageal reflux disease in Asia-Pacific

09 Sep 2021 by

The treatment of gastroesophageal reflux disease (GERD) continues to rely on proton pump inhibitors (PPIs), but advances in the field take account of new management options, such as antireflux surgery for reflux hypersensitivity and diaphragmatic breathing in refractory GERD or rumination, as pointed out during a lecture presented at this year’s virtual Asian Pacific Digestive Week (APDW 2021).

Best practices for gastroesophageal reflux disease in Asia-Pacific

09 Sep 2021

News & Updates

Filter by Specialty:

Specialty:

Vonoprazan bests PPIs in relieving GERD symptoms in latest meta-analysis

Vonoprazan bests PPIs in relieving GERD symptoms in latest meta-analysis

Cannabis, cannabinoids do not induce clinical remission but improve symptoms, QOL in IBD

Cannabis, cannabinoids do not induce clinical remission but improve symptoms, QOL in IBD

Vonoprazan-based regimen shows treatment potential against H. pylori

Vonoprazan-based regimen shows treatment potential against H. pylori

TDF better than entecavir at reducing HCC risk, improving survival in CHB patients

TDF better than entecavir at reducing HCC risk, improving survival in CHB patients

Does PPI use affect clinical outcomes in COVID-19 patients?

Does PPI use affect clinical outcomes in COVID-19 patients?

Vitamin D supplementation beneficial in children with IBD

Vitamin D supplementation beneficial in children with IBD

Double immunochemical faecal occult blood test most cost-effective CRC screening strategy

Double immunochemical faecal occult blood test most cost-effective CRC screening strategy

Reduced-dose S1 + oxaliplatin combo therapy preserves QoL in older patients with mCRC

Reduced-dose S1 + oxaliplatin combo therapy preserves QoL in older patients with mCRC

Antibiotic exposure tied to increased early-onset CRC risk

Antibiotic exposure tied to increased early-onset CRC risk

Best practices for gastroesophageal reflux disease in Asia-Pacific

Best practices for gastroesophageal reflux disease in Asia-Pacific